We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
News

BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types

BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
News

BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BiPar Sciences, Inc. has announced molecular biomarker data demonstrating the overexpression of the PARP (poly-ADP-ribose polymerase) protein in multiple cancers, including ovarian, breast and lung tumors. The research is the first demonstration of PARP overexpression in specific types of cancer. This insight is being used to guide the clinical development of the company's pipeline of PARP inhibitor candidates.

The results were presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

"These results allow us to focus our clinical development plan for BSI-201 by targeting tumors types that have the greatest probability of clinical success," said BiPar Executive Vice President Barry Sherman, M.D.

BiPar researchers used the Gene Logic Inc. BioExpress® System database to analyze PARP-1 gene expression in all types of primary human cancer and compared the results to normal counterpart tissue.

PARP expression was above the 95 percent upper confidence limit for normal tissue in ovarian cancer, intraductal breast cancer, lung cancer and uterine cancer. In contrast, prostate tumor tissue showed minimal PARP overexpression.

Advertisement